Effects of probiotic supplementation on gastrointestinal motility, inflammation, motor and non-motor symptoms in Parkinson's disease: a meta-analysis of randomized controlled trials
Abstract Parkinson’s disease (PD) is the second most common neurodegenerative disease. It is believed that “gut dysbiosis” can cause PD; therefore, whether probiotics can be used as adjuvants in the treatment of PD is being actively investigated. We performed a systematic review and meta-analysis to evaluate the effectiveness of probiotic therapy in PD patients. PUBMED/MEDLINE, EMBASE, Cochrane, Scopus, PsycINFO and Web of Science databases were searched till January 9, 2023. The meta-analysis used a random effects model and the effect size was calculated as mean difference or standardized mean difference. Ten studies with 760 participants were included in the final analysis. The meta-analysis revealed a significant improvement in gastrointestinal motility (standardized mean difference [95% confidence interval]) (0.78 [0.57-0.98]) and antioxidant capacity (1.73 [0.26 to 3.21]). Serum inflammatory markers (-8.64 [-16.05 to -1.23]), diabetes risk (-3.41 [-4.65 to -2.17]), Unified PD Rating Scale Part III (-4.12 [-7.81 to -0.43]), non-motor symptom (-5.55 [-8.30 to -2.80]), quality of life (-1.13 [-1.86 to -0.40]), anxiety scale (-2.21 [-3.41 to -1.00]) and depression scale (-1.53 [-1.99 to -1.07]) demonstrated a significant decrease. The Bristol stool scale, constipation and risk of dyslipidemia were not significantly improved. In a subgroup analysis, capsules further improved gastrointestinal motility than fermented milk. This review found that probiotic supplements may be suitable for increasing gastrointestinal motility, reducing inflammation, and improving motor and non-motor symptoms of PD. Further research is warranted to determine the mechanism of action of probiotics and the optimal treatment protocol..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ResearchSquare.com - (2023) vom: 18. Jan. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Park, Jong Mi [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-2461162/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA03842262X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA03842262X | ||
| 003 | DE-627 | ||
| 005 | 20230429195241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230117s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-2461162/v1 |2 doi | |
| 035 | |a (DE-627)XRA03842262X | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-2461162/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Park, Jong Mi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of probiotic supplementation on gastrointestinal motility, inflammation, motor and non-motor symptoms in Parkinson's disease: a meta-analysis of randomized controlled trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Parkinson’s disease (PD) is the second most common neurodegenerative disease. It is believed that “gut dysbiosis” can cause PD; therefore, whether probiotics can be used as adjuvants in the treatment of PD is being actively investigated. We performed a systematic review and meta-analysis to evaluate the effectiveness of probiotic therapy in PD patients. PUBMED/MEDLINE, EMBASE, Cochrane, Scopus, PsycINFO and Web of Science databases were searched till January 9, 2023. The meta-analysis used a random effects model and the effect size was calculated as mean difference or standardized mean difference. Ten studies with 760 participants were included in the final analysis. The meta-analysis revealed a significant improvement in gastrointestinal motility (standardized mean difference [95% confidence interval]) (0.78 [0.57-0.98]) and antioxidant capacity (1.73 [0.26 to 3.21]). Serum inflammatory markers (-8.64 [-16.05 to -1.23]), diabetes risk (-3.41 [-4.65 to -2.17]), Unified PD Rating Scale Part III (-4.12 [-7.81 to -0.43]), non-motor symptom (-5.55 [-8.30 to -2.80]), quality of life (-1.13 [-1.86 to -0.40]), anxiety scale (-2.21 [-3.41 to -1.00]) and depression scale (-1.53 [-1.99 to -1.07]) demonstrated a significant decrease. The Bristol stool scale, constipation and risk of dyslipidemia were not significantly improved. In a subgroup analysis, capsules further improved gastrointestinal motility than fermented milk. This review found that probiotic supplements may be suitable for increasing gastrointestinal motility, reducing inflammation, and improving motor and non-motor symptoms of PD. Further research is warranted to determine the mechanism of action of probiotics and the optimal treatment protocol. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Lee, Sang Chul |e verfasserin |4 aut | |
| 700 | 1 | |a Ham, Chorom |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Yong Wook |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2023) vom: 18. Jan. |
| 773 | 1 | 8 | |g year:2023 |g day:18 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-2461162/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 18 |c 01 | ||